Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn’s Disease Patients
ABSTRACT The fecal microbiota is a rich source of biomarkers that have previously been shown to be predictive of numerous disease states. Less well studied is the effect of immunomodulatory therapy on the microbiota and its role in response to therapy. This study explored associations between the fe...
Main Authors: | Matthew K. Doherty, Tao Ding, Charlie Koumpouras, Shannon E. Telesco, Calixte Monast, Anuk Das, Carrie Brodmerkel, Patrick D. Schloss |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2018-05-01
|
Series: | mBio |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/mBio.02120-17 |
Similar Items
-
Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Diseasesummary
by: Anna-Maria Globig, et al.
Published: (2021-01-01) -
Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond
by: Thomas J. Borody, et al.
Published: (2015-07-01) -
Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis
by: Julie Hejl, et al.
Published: (2018-03-01) -
Fecal microbiota transplant – a new frontier in inflammatory bowel disease
by: Sunkara T, et al.
Published: (2018-08-01) -
Predictive Factors of Surgical Recurrence in Patients with Crohn’s Disease on Long-Term Follow-Up: A Focus on Histology
by: Gian Paolo Caviglia, et al.
Published: (2022-08-01)